Relaxin as a Cure for Fibrosis

Until recently, relaxin has been known as a hormone that pertained to the female reproductive system. Its ability to remodel the extracellular matrix is responsible for its known reproductive effects. Current research has indicated that it may be useful as a drug to combat fibrosis. Relaxin has been proposed as an antifibrotic drug to target a variety of organs, including the skin, lung, kidney, liver, and heart. Studies done using the relaxin null knockout mouse have given scientists insight into the workings of this hormone. Human studies have also been done to test the efficacy of relaxin in its reversal of fibrosis. With more research, perhaps relaxin can be used as a drug in the future

HYDROCYCLIC AFFECTING OF FLUSH FLUID ON A STOPE BACK OF DRILLING FLUID

In article influencing of cyclic affectings of flush fluid on a stressed state of rocks of a bottom-hole zone is esteemed at boring oil and gas wells. By numerical experiments it is demonstrated that picking up rational arguments of hydrocyclic affecting of flush fluid

Uroflowmetric Monitoring and its Role in Evaluating the Results of Surgical Treatment in Children with Urethral Valves

This paper presents the results of research and treatments in 41 children (from two months to 15 years of age) with urethral valves. In all, 16 patients were treated using the endoscopic method, 7 patients by employing the polyethylene urethrotome and 18 patients treated by the proposed method, using a metallic urethrotome. Diagnosis of the urethral valves was done using ultrasonography, voiding cystourethrogram, urethrocystoscopy, uroflowmetry and cystomanometry. Mathematical modeling was applied to assess the treatment methods. The proposed method, using the metallic urethrotome, was preferable to the endoscopic method

The PROVe study: US real-world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma

BACKGROUND: Chlormethine/mechlorethamine gel is a skin-directed therapy for patients with mycosis fungoides cutaneous T-cell lymphoma. Currently, real-world data on chlormethine gel are lacking. OBJECTIVE: Our objective was to analyze the effect of chlormethine gel in combination with other therapies on efficacy, safety, and health-related quality of life in a real-world setting. METHODS: This prospective, observational study enrolled adult patients actively using chlormethine gel. Patients were monitored for up to 2 years during standard-of-care clinic visits. No specific visit schedules or clinical assessments, with the exception of patient-completed questionnaires, were mandated because of the expected variability in practice patterns. The primary efficacy endpoint was the proportion of patients with stage IA-IB disease receiving chlormethine + topical corticosteroids + other with ≥ 50% decrease in body surface area from baseline to 12 months. Response was assessed at each visit using by-time analysis, which investigates the trend to treatment response and allows assessment of response over time. Health-related quality of life was assessed with the Skindex-29 questionnaire. RESULTS: In total, 298 patients were monitored. At 12 months post-treatment initiation, 44.4% (chlormethine + topical corticosteroids + other) and 45.1% (patients receiving chlormethine + other treatment) of efficacy-evaluable patients were responders. By-time analysis demonstrated that peak response occurred (chlormethine + other; 66.7%) at 18 months. There was a significant correlation between responder status and lower post-baseline Skindex-29 scores. CONCLUSIONS: This real-world study confirmed that chlormethine gel is an important therapeutic option for patients with mycosis fungoides and contributes to reducing the severity of skin lesions and improving health-related quality of life